Management of Breakthrough Bleeding with Hormone Replacement Therapy

Introduction to Breakthrough Bleeding Management

The American College of Obstetricians and Gynecologists recommends switching to a continuous combined HRT regimen using transdermal 17β-estradiol with micronized progesterone 100 mg daily to prevent withdrawal bleeding and resolve breakthrough bleeding within 3 months 1, 2

The Endocrine Society suggests using transdermal 17β-estradiol (50-100 μg daily) plus micronized progesterone 100 mg daily continuously as the preferred first-choice regimen 1, 2, 3
This approach prevents withdrawal bleeding entirely while providing superior endometrial protection 1
Micronized progesterone is strongly preferred over synthetic progestins due to lower cardiovascular and thrombotic risk 1, 4
Breakthrough bleeding is expected to resolve within the first 3 months of proper continuous therapy 5, 3

If a patient strongly prefers to maintain withdrawal bleeding, the European Society of Human Reproduction and Embryology recommends optimizing the sequential regimen by increasing progestogen dose and/or duration to ensure adequate endometrial protection 1
Using micronized progesterone 200 mg daily for 12-14 days per month (not less than 12 days) is suggested 1, 6, 5, 3

The American College of Obstetricians and Gynecologists recommends reassessing at 3 months to evaluate bleeding pattern and treatment response 5, 3
Treatment effectiveness should be evaluated after 3-6 months of any new regimen 3

The recommendation for continuous combined HRT is based on multiple high-quality guidelines, including ESHRE consensus recommendations, with supporting evidence from randomized controlled trials showing significantly fewer bleeding days with optimized continuous regimens 4, 1, 5, 3

Increasing micronised progesterone to 200 mg daily for 12-14 days per month is crucial for adequate endometrial protection, regardless of the delivery method, as recommended by the Human Reproduction Update guideline society 7
The European Society of Human Reproduction and Embryology suggests that higher progestogen doses prevent breakthrough bleeding when oestrogen doses are increased, and this applies equally to patches or gel/progesterone combinations, as reported in Blood Reviews 8
The use of micronised progesterone in sequential regimens produces more irregular bleeding episodes compared to synthetic progestogens, but it remains the preferred choice due to its superior cardiovascular and thrombotic safety profiles, as stated in Blood Reviews 9

Micronised progesterone should be the progestogen of choice due to its minimal cardiovascular risk, lowest thrombotic risk profile, and neutral or beneficial effects on blood pressure, as recommended by the Blood Reviews guideline society 9

Optimising sequential regimen by increasing micronised progesterone to 200 mg daily for 12-14 days per month is a recommended approach if continuous therapy is refused, as suggested by the Human Reproduction Update guideline society 7
The International Menopause Society suggests that this approach works equally with patches or gel, and it is essential to reassess at 3 months to ensure bleeding resolution, as reported in Blood Reviews 8 and 9